Results 171 to 180 of about 7,493 (302)

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao   +4 more
wiley   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

open access: yesPrecision Medical Sciences, EarlyView.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

Combined Exposure to Ecologically Relevant Concentrations of Atrazine and Microcystin Causes Morphological Changes in the Hepatopancreas of Crayfish. [PDF]

open access: yesIntegr Comp Biol
Reddy SG   +18 more
europepmc   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

open access: yesPrecision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang   +7 more
wiley   +1 more source

Cyanobacteria in Spanish reservoirs. How frequently are they toxic? [PDF]

open access: yes, 2004
Carrasco, D., Quesada, A., Sanchis, D.
core  

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Home - About - Disclaimer - Privacy